Allergen-specific immunotherapy offers the only disease-modifying treatment for canine atopic dermatitis, providing long-term welfare improvement by reducing allergic reactivity rather than suppressing symptoms.
Immunotherapy addresses atopic dermatitis at its root cause rather than suppressing the inflammatory response it generates. For the 50-70% of dogs who respond, immunotherapy can dramatically reduce dependence on long-term medications with associated side effects, while providing sustained relief from the chronic itch that diminishes quality of life. The 12-24 month commitment before full efficacy is established requires owner persistence, but represents an investment in long-term welfare improvement that symptomatic medications alone cannot achieve. Good candidate selection by a veterinary dermatologist maximizes the welfare return on this investment.